Exagen (XGN) Competitors $8.99 +0.08 (+0.90%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$8.90 -0.09 (-0.95%) As of 08/7/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XGN vs. AVAH, AGL, CDNA, FLGT, FTRE, PSNL, AUNA, LFMD, OMDA, and SBCShould you be buying Exagen stock or one of its competitors? The main competitors of Exagen include Aveanna Healthcare (AVAH), Agilon Health (AGL), CareDx (CDNA), Fulgent Genetics (FLGT), Fortrea (FTRE), Personalis (PSNL), Auna (AUNA), LifeMD (LFMD), Omada Health (OMDA), and SBC Medical Group (SBC). These companies are all part of the "healthcare" industry. Exagen vs. Its Competitors Aveanna Healthcare Agilon Health CareDx Fulgent Genetics Fortrea Personalis Auna LifeMD Omada Health SBC Medical Group Aveanna Healthcare (NASDAQ:AVAH) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings. Do analysts rate AVAH or XGN? Aveanna Healthcare currently has a consensus target price of $5.25, suggesting a potential downside of 9.64%. Exagen has a consensus target price of $11.25, suggesting a potential upside of 25.14%. Given Exagen's stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than Aveanna Healthcare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aveanna Healthcare 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Exagen 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer AVAH or XGN? In the previous week, Exagen had 13 more articles in the media than Aveanna Healthcare. MarketBeat recorded 18 mentions for Exagen and 5 mentions for Aveanna Healthcare. Aveanna Healthcare's average media sentiment score of 0.90 beat Exagen's score of 0.26 indicating that Aveanna Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aveanna Healthcare 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exagen 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation and earnings, AVAH or XGN? Aveanna Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Aveanna Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAveanna Healthcare$2.09B0.54-$10.93M$0.02290.50Exagen$58.86M3.36-$15.11M-$0.89-10.10 Is AVAH or XGN more profitable? Aveanna Healthcare has a net margin of 0.26% compared to Exagen's net margin of -28.85%. Aveanna Healthcare's return on equity of -15.16% beat Exagen's return on equity.Company Net Margins Return on Equity Return on Assets Aveanna Healthcare0.26% -15.16% 1.14% Exagen -28.85%-130.38%-34.69% Which has more volatility & risk, AVAH or XGN? Aveanna Healthcare has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Do institutionals and insiders hold more shares of AVAH or XGN? 88.0% of Aveanna Healthcare shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 7.8% of Aveanna Healthcare shares are held by insiders. Comparatively, 12.6% of Exagen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryAveanna Healthcare beats Exagen on 10 of the 16 factors compared between the two stocks. Get Exagen News Delivered to You Automatically Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XGN vs. The Competition Export to ExcelMetricExagenMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$196.06M$10.35B$5.48B$9.57BDividend YieldN/A2.02%3.99%4.17%P/E Ratio-10.1019.2529.9425.14Price / Sales3.3623.11398.9486.71Price / CashN/A21.8135.9458.58Price / Book9.362.848.105.59Net Income-$15.11M$211.77M$3.26B$265.48M7 Day Performance4.17%1.54%0.68%1.22%1 Month Performance29.35%2.31%2.46%0.39%1 Year Performance225.72%-11.48%27.69%23.47% Exagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XGNExagen4.5524 of 5 stars$8.99+0.9%$11.25+25.1%+266.9%$196.06M$58.86M-10.10220AVAHAveanna Healthcare0.7584 of 5 stars$3.82+2.1%$5.25+37.4%+69.4%$729.65M$2.02B191.0033,500News CoverageGap UpAGLAgilon Health1.9407 of 5 stars$1.82+6.8%$4.71+159.7%-84.7%$703.72M$6.06B-3.081,076Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap DownCDNACareDx4.2143 of 5 stars$12.60+3.1%$29.33+132.8%-50.3%$680.42M$333.79M10.96740Earnings ReportGap DownFLGTFulgent Genetics3.784 of 5 stars$18.36-0.9%$23.00+25.3%-13.2%$564.12M$283.47M-11.061,313Earnings ReportAnalyst UpgradeFTREFortrea4.0022 of 5 stars$6.42+17.6%$13.73+113.8%-70.5%$494.13M$2.70B-0.7315,500Trending NewsEarnings ReportAnalyst ForecastGap UpPSNLPersonalis3.8382 of 5 stars$5.57+3.3%$7.67+37.6%+58.0%$476.07M$84.61M-4.32400Earnings ReportAnalyst ForecastAUNAAuna3.4742 of 5 stars$6.25+1.2%$10.70+71.3%-17.0%$456.66M$1.17B10.7714,842LFMDLifeMD2.1628 of 5 stars$12.35+24.2%$13.86+12.2%+23.1%$451.75M$212.45M-36.32230News CoverageAnalyst ForecastHigh Trading VolumeOMDAOmada HealthN/A$17.84+2.6%$23.86+33.7%N/A$447.54MN/A0.00849News CoverageEarnings ReportSBCSBC Medical GroupN/A$4.32+3.3%N/AN/A$433.10M$205.42M0.00N/AUpcoming Earnings Related Companies and Tools Related Companies AVAH Alternatives AGL Alternatives CDNA Alternatives FLGT Alternatives FTRE Alternatives PSNL Alternatives AUNA Alternatives LFMD Alternatives OMDA Alternatives SBC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XGN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
